{
  "meta": {
    "title": "23_Hepatitis",
    "url": "https://brainandscalpel.vercel.app/23-hepatitis-5cd1364e.html",
    "scrapedAt": "2025-11-30T12:29:32.061Z"
  },
  "questions": [
    {
      "text": "Which of the following is a non-enveloped virus that causes hepatitis?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis C"
        },
        {
          "id": 2,
          "text": "Hepatitis B"
        },
        {
          "id": 3,
          "text": "Hepatitis A"
        },
        {
          "id": 4,
          "text": "Hepatitis D"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Hepatitis A</strong> and <strong>E</strong> are <strong>non-enveloped</strong> viruses, while Hepatitis<strong> B, C, and D</strong> are <strong>enveloped</strong> viruses.</p><hr><h3>Related Pearl: Enveloped and non-enveloped viruses</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Non-enveloped viruses</strong></td>\n<td><strong>Enveloped viruses</strong></td>\n</tr>\n<tr>\n<td><strong>DNA viruses</strong></td>\n<td>\n<p>Parvovirus</p>\n<p>Adenovirus</p>\n</td>\n<td>\n<p>Herpes virus</p>\n<p>Hepatitis B virus</p>\n<p>Poxvirus</p>\n</td>\n</tr>\n<tr>\n<td><strong>RNA viruses</strong></td>\n<td>\n<p>Picornavirus</p>\n<p>Astrovirus</p>\n<p>Reovirus</p>\n<p>Calicivirus</p>\n<p>Hepatitis A and E virus</p>\n</td>\n<td>\n<p>Hepatitis c virus</p>\n<p>Rubella virus</p>\n<p>Chikungunya virus</p>\n<p>Dengue virus</p>\n<p>Japanese encephalitis virus</p>\n<p>Kyasanur Forest disease virus</p>\n<p>Zika virus</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7593",
      "difficulty": "easy"
    },
    {
      "text": "A 25-year-old man hailing from Mumbai presents to you with complaints of abdominal pain and malaise. On examination, he is icteric and the liver is palpable 6 cm below the costal margin. On further questioning, he informs you that a few weeks back the drains surrounding his house were overflowing due to the monsoon flooding. Which of the following is the most likely etiology?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis A or D"
        },
        {
          "id": 2,
          "text": "Hepatitis B or E"
        },
        {
          "id": 3,
          "text": "Hepatitis A or B"
        },
        {
          "id": 4,
          "text": "Hepatitis A or E"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given case scenario with icterus, hepatomegaly, and environmental history is suggestive of acute viral hepatitis, likely to be caused by <strong>hepatitis A or E</strong> viruses.&nbsp;</p>\n<p><strong>Hepatitis A</strong> and<strong> E </strong>are transmitted&nbsp;by<strong>&nbsp;feco-oral </strong>route. Overcrowding, poor hygiene, and fecal contamination of water supplies such as after monsoon flooding can lead to spreading of the disease.&nbsp;</p>\n<p><strong>Hepatitis B, C,</strong> and<strong> D</strong> are transmitted by <strong>parenteral</strong> routes, e.g. blood transfusions.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7594",
      "difficulty": "easy"
    },
    {
      "text": "A 18-year-old man presents with fever, diarrhea, and jaundice. He gives a history of consuming food at a roadside stall. Which of the following statements is incorrect about the etiological agent?",
      "choices": [
        {
          "id": 1,
          "text": "It belongs to family Hepatoviridae"
        },
        {
          "id": 2,
          "text": "Majority of infections are symptomatic"
        },
        {
          "id": 3,
          "text": "It is transmitted by feco-oral route"
        },
        {
          "id": 4,
          "text": "A formalin inactivated vaccine is used for prevention"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario is suggestive of <strong>viral hepatitis</strong> which is most likely to be <strong>Hepatitis A</strong>. Hepatitis A virus belongs to the family¬†<strong>Picornaviridae</strong>. It is transmitted by <strong>feco-oral route¬†</strong>and most of the infections are <strong>symptomatic</strong>.</p>\n<p>There is no definitive treatment, thus, only <strong>supportive therapy</strong> is given.</p>\n<p>¬†</p><p>A safe and effective vaccine named<strong> HAVRIX</strong> is available to prevent hepatitis A infection. It is a formalin-inactivated, alum-conjugated vaccine.</p><hr><h3>Related Pearl: The Hepatitis Viruses</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>HAV</td>\n<td>HBV</td>\n<td>HCV</td>\n<td>HDV</td>\n<td>HEV</td>\n</tr>\n<tr>\n<td>Specific name</td>\n<td>Hepatovirus A</td>\n<td>Hepatitis B virus</td>\n<td>Hepacivirus C</td>\n<td>Hepatitis D virus</td>\n<td>Orthohepevirus A</td>\n</tr>\n<tr>\n<td>Family</td>\n<td>Picornaviridae</td>\n<td>Hepadnaviridae</td>\n<td>Flaviviridae</td>\n<td>Kolmioviridae (genus deltavirus)</td>\n<td>Hepeviridae</td>\n</tr>\n<tr>\n<td>Envelope</td>\n<td>Non enveloped</td>\n<td>Enveloped</td>\n<td>Enveloped</td>\n<td>Envelope from HBV</td>\n<td>Quasi-enveloped</td>\n</tr>\n<tr>\n<td>Nuclear material</td>\n<td>ssRNA</td>\n<td>Partially dsDNA</td>\n<td>ssRNA</td>\n<td>Circular defective ssRNA</td>\n<td>ssRNA</td>\n</tr>\n<tr>\n<td>Antigens</td>\n<td>HAV Ag</td>\n<td>HBsAg, HBcAg, HBeAg, HBxAg</td>\n<td>HCV Ag</td>\n<td>HBsAg, HDAg</td>\n<td>HEV Ag</td>\n</tr>\n<tr>\n<td>Antibodies</td>\n<td>Anti-HAV Ab</td>\n<td>Anti-HBs Ab, Anti-HBc Ab, Anti-HBe Ab</td>\n<td>Anti-HCV Ab</td>\n<td>Anti-HBs Ab, Anti-HDV Ab</td>\n<td>Anti-HEV Ab</td>\n</tr>\n<tr>\n<td>Auto-antibodies</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>Anti-LKM 1</td>\n<td>Anti-LKM 3</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Routes of transmission</td>\n<td>Feco-oral, parenteral, sexual</td>\n<td>Perinatal, parenteral, sexual, percutaneous, direct mucosal contact</td>\n<td>Parenteral, perinatal, percutaneous, sexual</td>\n<td>Parenteral, sexual</td>\n<td>Feco-oral, zoonotic, vertical</td>\n</tr>\n<tr>\n<td>Incubation period</td>\n<td>30 days</td>\n<td>60 days</td>\n<td>50 days</td>\n<td>60 days</td>\n<td>40 days</td>\n</tr>\n<tr>\n<td>Chances of fulminant hepatic failure</td>\n<td>0.1%</td>\n<td>0.1 to 1%</td>\n<td>0.1%</td>\n<td>5% in coinfections and 20% in superinfections</td>\n<td>1-2% in adults and up to 25% in pregnant women</td>\n</tr>\n<tr>\n<td>Extrahepatic manifestations</td>\n<td>Rash, arthralgia</td>\n<td>Polyarteritis nodosa and membranous nephropathy</td>\n<td>Essential mixed cryoglobulinemia, MPGN, Metabolic syndrome</td>\n<td>&nbsp; &nbsp; &nbsp; -</td>\n<td>GBS, Bell&rsquo;s palsy, pancreatitis, &nbsp;and glomerulonephritis</td>\n</tr>\n<tr>\n<td>Resolution of acute infection</td>\n<td>2 months</td>\n<td>6 months</td>\n<td>6 months</td>\n<td>6 months</td>\n<td>3 months</td>\n</tr>\n<tr>\n<td>Progression to chronic infection</td>\n<td>No</td>\n<td>5-10%</td>\n<td>&gt;80%</td>\n<td>\n<p>10% of co-infections,</p>\n<p>90&ndash;100% of superinfections</p>\n</td>\n<td>\n<p>Only in immuno-compromised</p>\n</td>\n</tr>\n<tr>\n<td>HCC</td>\n<td>No</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n</tr>\n<tr>\n<td>Vaccine</td>\n<td>Available</td>\n<td>Available</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-</td>\n<td>HBV vaccine</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -</td>\n</tr>\n<tr>\n<td>Therapy</td>\n<td>None</td>\n<td>Entecavir, tenofovir, pegIFN-ùõÇ</td>\n<td>Velpatasvir, sofosbuvir, ribavirin</td>\n<td>PegIFN-ùõÇ</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7595",
      "difficulty": "medium"
    },
    {
      "text": "What is the average incubation period for Hepatitis A virus?",
      "choices": [
        {
          "id": 1,
          "text": "<1 week"
        },
        {
          "id": 2,
          "text": "30 days"
        },
        {
          "id": 3,
          "text": "90 days"
        },
        {
          "id": 4,
          "text": "120 days"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The average <strong>incubation period</strong> of&nbsp;the<strong> Hepatitis A virus&nbsp;</strong>(HAV)&nbsp;is around <strong>30</strong> <strong>days</strong>.&nbsp;It ranges from 15-50 days.&nbsp;The clinical disease has a <strong>prodromal stage</strong> and an <strong>icteric stage</strong>.</p><hr><h3>Related Pearl: The Hepatitis Viruses</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>HAV</td>\n<td>HBV</td>\n<td>HCV</td>\n<td>HDV</td>\n<td>HEV</td>\n</tr>\n<tr>\n<td>Specific name</td>\n<td>Hepatovirus A</td>\n<td>Hepatitis B virus</td>\n<td>Hepacivirus C</td>\n<td>Hepatitis D virus</td>\n<td>Orthohepevirus A</td>\n</tr>\n<tr>\n<td>Family</td>\n<td>Picornaviridae</td>\n<td>Hepadnaviridae</td>\n<td>Flaviviridae</td>\n<td>Kolmioviridae (genus deltavirus)</td>\n<td>Hepeviridae</td>\n</tr>\n<tr>\n<td>Envelope</td>\n<td>Non enveloped</td>\n<td>Enveloped</td>\n<td>Enveloped</td>\n<td>Envelope from HBV</td>\n<td>Quasi-enveloped</td>\n</tr>\n<tr>\n<td>Nuclear material</td>\n<td>ssRNA</td>\n<td>Partially dsDNA</td>\n<td>ssRNA</td>\n<td>Circular defective ssRNA</td>\n<td>ssRNA</td>\n</tr>\n<tr>\n<td>Antigens</td>\n<td>HAV Ag</td>\n<td>HBsAg, HBcAg, HBeAg, HBxAg</td>\n<td>HCV Ag</td>\n<td>HBsAg, HDAg</td>\n<td>HEV Ag</td>\n</tr>\n<tr>\n<td>Antibodies</td>\n<td>Anti-HAV Ab</td>\n<td>Anti-HBs Ab, Anti-HBc Ab, Anti-HBe Ab</td>\n<td>Anti-HCV Ab</td>\n<td>Anti-HBs Ab, Anti-HDV Ab</td>\n<td>Anti-HEV Ab</td>\n</tr>\n<tr>\n<td>Auto-antibodies</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>Anti-LKM 1</td>\n<td>Anti-LKM 3</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Routes of transmission</td>\n<td>Feco-oral, parenteral, sexual</td>\n<td>Perinatal, parenteral, sexual, percutaneous, direct mucosal contact</td>\n<td>Parenteral, perinatal, percutaneous, sexual</td>\n<td>Parenteral, sexual</td>\n<td>Feco-oral, zoonotic, vertical</td>\n</tr>\n<tr>\n<td>Incubation period</td>\n<td>30 days</td>\n<td>60 days</td>\n<td>50 days</td>\n<td>60 days</td>\n<td>40 days</td>\n</tr>\n<tr>\n<td>Chances of fulminant hepatic failure</td>\n<td>0.1%</td>\n<td>0.1 to 1%</td>\n<td>0.1%</td>\n<td>5% in coinfections and 20% in superinfections</td>\n<td>1-2% in adults and up to 25% in pregnant women</td>\n</tr>\n<tr>\n<td>Extrahepatic manifestations</td>\n<td>Rash, arthralgia</td>\n<td>Polyarteritis nodosa and membranous nephropathy</td>\n<td>Essential mixed cryoglobulinemia, MPGN, Metabolic syndrome</td>\n<td>&nbsp; &nbsp; &nbsp; -</td>\n<td>GBS, Bell&rsquo;s palsy, pancreatitis, &nbsp;and glomerulonephritis</td>\n</tr>\n<tr>\n<td>Resolution of acute infection</td>\n<td>2 months</td>\n<td>6 months</td>\n<td>6 months</td>\n<td>6 months</td>\n<td>3 months</td>\n</tr>\n<tr>\n<td>Progression to chronic infection</td>\n<td>No</td>\n<td>5-10%</td>\n<td>&gt;80%</td>\n<td>\n<p>10% of co-infections,</p>\n<p>90&ndash;100% of superinfections</p>\n</td>\n<td>\n<p>Only in immuno-compromised</p>\n</td>\n</tr>\n<tr>\n<td>HCC</td>\n<td>No</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n</tr>\n<tr>\n<td>Vaccine</td>\n<td>Available</td>\n<td>Available</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-</td>\n<td>HBV vaccine</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -</td>\n</tr>\n<tr>\n<td>Therapy</td>\n<td>None</td>\n<td>Entecavir, tenofovir, pegIFN-ùõÇ</td>\n<td>Velpatasvir, sofosbuvir, ribavirin</td>\n<td>PegIFN-ùõÇ</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7596",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is called as Australia antigen?",
      "choices": [
        {
          "id": 1,
          "text": "HBsAg"
        },
        {
          "id": 2,
          "text": "HBeAg"
        },
        {
          "id": 3,
          "text": "HBcAg"
        },
        {
          "id": 4,
          "text": "HBV-DNA"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p class=\"p1\"><strong>HBsAg</strong> (Hepatitis B surface antigen) is also known as the <strong>Australia antigen</strong>.&nbsp;It is called so because it was first isolated from the serum of an Australian person.</p>\n<p class=\"p1\">Sera from hepatitis B patients when observed under an electron microscope show three types of particles:</p>\n<ul>\n<li>A&nbsp;<strong>spherical</strong> particle: 22nm, most abundant, contains only HBsAg.</li>\n<li><strong>Filamentous</strong> or tubular particle: 22nm, contains only HBsAg.</li>\n<li>A&nbsp;<strong>double</strong>-<strong>walled</strong> <strong>spherical</strong> structure: 42nm diameter, is the complete Hepatitis B virus. It was described by Dane and is called Dane particle.&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2ec3c3dc9d664d14b35c4956644ef3dbx1279x1066.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3196",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is also referred to as Dane particle?",
      "choices": [
        {
          "id": 1,
          "text": "HAV"
        },
        {
          "id": 2,
          "text": "HBV"
        },
        {
          "id": 3,
          "text": "HCV"
        },
        {
          "id": 4,
          "text": "HDV"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Dane particle</strong> refers to Hepatitis B.</p>\n<p class=\"p1\">Sera from <strong>hepatitis B</strong> patients when observed under an electron microscope show three types of particles:</p>\n<ul>\n<li><strong>Spherical</strong>&nbsp;particle: 22nm, most abundant, contains only HBsAg.</li>\n<li><strong>Filamentous</strong>&nbsp;or tubular particle: 22nm, contains only HBsAg.</li>\n<li>A&nbsp;<strong>double</strong>-<strong>walled</strong>&nbsp;<strong>spherical</strong>&nbsp;structure: 42nm diameter, is the complete Hepatitis B virus. It was described by Dane and is called Dane particle.&nbsp;</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2871297dab034914b391c2d3e6e40f12x1280x1066.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7597",
      "difficulty": "easy"
    },
    {
      "text": "A 35-year-old male patient with chronic hepatitis B has high levels of serum HBeAg. Which of the following viral genes is involved in coding the same?",
      "choices": [
        {
          "id": 1,
          "text": "C gene"
        },
        {
          "id": 2,
          "text": "S gene"
        },
        {
          "id": 3,
          "text": "P gene"
        },
        {
          "id": 4,
          "text": "X gene"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>HBeAg is coded by the <strong>C gene.&nbsp;</strong>The presence of high levels of <strong>HBeAg&nbsp;</strong>(and HBV DNA) suggests high <strong>infectivity</strong>.&nbsp;</p>\n<p>HBV Genome has four overlapping genes. They code for:&nbsp;</p>\n<ul>\n<li><strong>S gene-</strong>It codes for surface antigen.&nbsp;</li>\n<li><strong>C gene-</strong>\n<ul>\n<li>When the&nbsp;<strong>C</strong> region alone is translated: <strong>HBcAg</strong> is formed.</li>\n<li>When translation begins from <strong>Pre C</strong> region, <strong>HBeAg</strong> is formed.</li>\n</ul>\n</li>\n<li><strong>P gene-&nbsp;</strong>Codes for DNA polymerase.</li>\n<li><strong>X gene-</strong> Codes for a non-particulate protein HBxAg.</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/406ad6c84ad341059b0d6f4ddd2383c2x1280x1492.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7598",
      "difficulty": "medium"
    },
    {
      "text": "While drawing blood from a patient with hepatitis B, it splashes into the eyes of a nurse. Which of the following markers will appear first in her blood if she gets infected?",
      "choices": [
        {
          "id": 1,
          "text": "HBeAg"
        },
        {
          "id": 2,
          "text": "HBsAg"
        },
        {
          "id": 3,
          "text": "Anti HBs"
        },
        {
          "id": 4,
          "text": "Anti HBe"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>HBsAg</strong> is the <strong>first</strong> marker to appear in the blood after infection.</p>\n<p>It can be detected even before the elevation of serum transaminases and onset of clinical illness.&nbsp;Usually, it&nbsp;<strong>disappears</strong> <strong>within 2 months</strong>&nbsp;of onset of clinical disease but may last for even 6 months and beyond. If it persists <strong>beyond 6 months</strong>, it indicates <strong>chronic hepatitis.</strong></p>\n<p>Anti-HBs is the protective antibody, which appears soon after HBsAg, disappears and remains in serum for a long time.</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7601",
      "difficulty": "easy"
    },
    {
      "text": "A patient with hepatitis B presents to OPD for follow-up. Which of the following serological markers will not be detected in his blood?",
      "choices": [
        {
          "id": 1,
          "text": "HBsAg"
        },
        {
          "id": 2,
          "text": "Anti-HBs"
        },
        {
          "id": 3,
          "text": "HBcAg"
        },
        {
          "id": 4,
          "text": "Anti-HBc"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Hepatitis B core antigen </strong>(<strong>HBcAg</strong>) is not present in blood because it is enclosed within the HBsAg coat. However, antibodies against HBc (Anti-HBc) are the <strong>earliest antibody markers&nbsp;</strong>to be seen in the blood after<strong> 1-2 weeks.</strong></p>\n<p>Note:</p>\n<ul>\n<li><strong>HBsAg</strong>: Earliest marker to be detected in the serum of Hepatitis B-infected persons.</li>\n<li><strong>Anti HBc</strong>: Earliest antibody to be detected in the serum of Hepatitis B-infected persons.</li>\n</ul>\n<p>The given image shows hepatitis B virus and its antigens</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2ea2899a9a1540d8af09eeaf3e5d41abx839x564.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7602",
      "difficulty": "easy"
    },
    {
      "text": "There are 3 to 5% healthy hepatitis B carriers in India who are asymptomatic. They are at the risk of developing hepatocellular carcinoma in the future because _________",
      "choices": [
        {
          "id": 1,
          "text": "They are unable to mount inflammation against the virus"
        },
        {
          "id": 2,
          "text": "Virus can integrate with host DNA and form complementary DNA"
        },
        {
          "id": 3,
          "text": "There is a risk of elevation of transaminases"
        },
        {
          "id": 4,
          "text": "Liver parenchymal cells are in a state of high proliferation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In most tumors,<strong> HBV DNA </strong>is<strong> integrated </strong>into the<strong> cell genome</strong>, and in most cases, the virus DNA has undergone rearrangements, including deletions. After integration, it promotes the overexpression of cell genes that can also contribute to oncogenesis.</p>\n<p>The only <strong>viral gene</strong> product that is consistently present in the <strong>tumor cells</strong> is the <strong>X protein</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9287",
      "difficulty": "easy"
    },
    {
      "text": "The given life cycle is suggestive of which of the following viruses?",
      "choices": [
        {
          "id": 1,
          "text": "HIV"
        },
        {
          "id": 2,
          "text": "Hepatitis B"
        },
        {
          "id": 3,
          "text": "Influenza"
        },
        {
          "id": 4,
          "text": "Herpes simplex"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given life cycle is of the&nbsp;<strong>hepatitis B virus.&nbsp;</strong></p>\n<p>Steps:&nbsp;</p>\n<ul>\n<li>The infectious virion <strong>attaches</strong> to cells and <strong>uncoating</strong> occurs.</li>\n<li>Cell enzymes in the hepatocytes convert dsDNA to&nbsp;covalently closed circular double-stranded DNA (c<strong>ccDNA)</strong></li>\n<li><strong>HBV mRNA</strong> and <strong>pre-genome RNA</strong> is synthesized using cccDNA as a <strong>template</strong>.</li>\n<li>pre-genome RNA is&nbsp;encapsidated by packaging signal into new core particles.</li>\n<li>These new core particles are templates for HBV reverse transcriptase.</li>\n<li><strong>Negative-strand DNA</strong> is synthesized by viral <strong>polymerase&nbsp;</strong>by reverse transcription.&nbsp;</li>\n<li>The cores bud from the pre-Golgi membranes, acquiring <strong>HBsAg-containing envelopes.</strong></li>\n<li>Once viral particles are assembled, they either <strong>exit</strong> the cell or cause <strong>reinfection of the same cell</strong>.&nbsp;</li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/af929726175f4dd5bd97d0a13eed1fc5.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB9162",
      "difficulty": "easy"
    },
    {
      "text": "A patient is diagnosed with Hepatitis B infection. Which of the following markers will always be present in his serum, even during recurrences, or if he develops chronic hepatitis?",
      "choices": [
        {
          "id": 1,
          "text": "HBc Ag"
        },
        {
          "id": 2,
          "text": "Anti HBs Ab"
        },
        {
          "id": 3,
          "text": "Anti HBc Ab"
        },
        {
          "id": 4,
          "text": "HBe Ag"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>A patient who has had exposure to HBV will have <strong>anti-HBc antibody</strong>&nbsp;even when he has moved into the chronic or recurrent stages.&nbsp;<strong>IgM</strong> anti-HBc reappears during acute&nbsp;<strong>recurrences</strong> while <strong>IgG</strong>&nbsp;anti-HBc is found in <strong>chronic</strong> states.&nbsp;</p>\n<p>The <strong>HBsAg</strong> antigen is present in <strong>chronic</strong> hepatitis B, while the antibody anti-HBs is not.</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC7690",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not synthesized by pre-core mutants of hepatitis B virus?",
      "choices": [
        {
          "id": 1,
          "text": "HBsAg"
        },
        {
          "id": 2,
          "text": "HBxAg"
        },
        {
          "id": 3,
          "text": "HBcAg"
        },
        {
          "id": 4,
          "text": "HBeAg"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Pre-core</strong> mutants of hepatitis B virus are unable to synthesize <strong>HBeAg.</strong></p>\n<p>In the <strong>HBV genome</strong>, the C gene consists of 2 regions:</p>\n<ul>\n<li><strong>Pre-C region</strong>- When translation begins from the <strong>Pre-C</strong> region, <strong>HBeAg</strong> is synthesized.</li>\n<li><strong>C-region</strong>- When it begins from the <strong>C-region,</strong> <strong>HBcAg</strong> is synthesized.</li>\n</ul>\n<p>In the¬†HBeAg sequence of <strong>pre-core mutants</strong>, there is a¬†<strong>G to A switch </strong>at the 28th amino acid, causing a<strong> stop codon.¬†</strong>Hence, pre-core mutants are unable to synthesize HBeAg.<strong>¬†</strong></p>\n<p>The image below shows the <strong>HBV genome :¬†</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/bc12fcbb29944360a738ae63d7059501x1280x1492.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7604",
      "difficulty": "medium"
    },
    {
      "text": "The serological profile of a patient is given below. What is your diagnosis?<div class='question-desc-html'><p>HBsAg: + ve<br />HBeAg: + ve<br />Anti HBc: IgM: + ve<br />Anti HBs: - ve<br />Anti HBe: - ve</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Acute HBV infection with high infectivity"
        },
        {
          "id": 2,
          "text": "HBV vaccination"
        },
        {
          "id": 3,
          "text": "Chronic HBV infection with high infectivity"
        },
        {
          "id": 4,
          "text": "Acute HBV infection with low infectivity"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>HBsAg</strong> and <strong>IgM Anti-HBc</strong>&nbsp;are positive, indicating an <strong>acute</strong> hepatitis B infection. <strong>HBeAg positive</strong> indicates that the patient is highly infectious.</p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7605",
      "difficulty": "easy"
    },
    {
      "text": "An HBsAg positive primigravida presents to you for routine antenatal care. She asks you about the risk of transmission of HBV to her baby. Which of the following is not related to the same?",
      "choices": [
        {
          "id": 1,
          "text": "Intrauterine transmission"
        },
        {
          "id": 2,
          "text": "Normal vaginal delivery"
        },
        {
          "id": 3,
          "text": "Forceps vaginal delivery"
        },
        {
          "id": 4,
          "text": "Breastfeeding"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Breastfeeding is not related to the vertical transmission of hepatitis B virus. <strong>Breastfeeding</strong> is <strong>not contraindicated</strong> in <strong>HBsAg-positive</strong> mothers.&nbsp;</p>\n<p id=\"__p7\" class=\"p p-first\">Mother-to-child transmission of HBV can occur via three modalities:</p>\n<ul>\n<li><strong>Intrauterine transmission</strong>- Transplacental transmission is uncommon. Another route is via a breach in the placental barrier exposing maternal blood to fetal blood e.g. - threatened preterm labor.&nbsp;</li>\n<li><strong>Transmission during delivery</strong>- It&nbsp;is the <strong>most frequent method</strong> of vertical transmission. It is mostly due to newborn contact with the mother&rsquo;s <strong>infected secretions</strong> or blood at the time of <strong>delivery</strong> (normal/instrumental).&nbsp;</li>\n<li><strong>Postpartum transmission</strong>- Though HBV DNA is present in breast milk, it is not transmitted to the fetus. However, cracked nipples expose the infant to maternal blood, and can transmit the virus to the infant.&nbsp;</li>\n</ul>\n<p>Immunoprophylaxis with <strong>HBIg</strong> is indicated for <strong>babies</strong> born to <strong>HBsAg-positive</strong> <strong>mothers</strong> followed by a three-dose <strong>hepatitis B</strong> recombinant<strong> vaccine</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3576",
      "difficulty": "easy"
    },
    {
      "text": "An intern takes a hepatitis B vaccine booster dose before his ward postings begin. Which of the following serological markers will indicate immunity against HBV in this case?",
      "choices": [
        {
          "id": 1,
          "text": "HBsAg"
        },
        {
          "id": 2,
          "text": "Anti-HBs"
        },
        {
          "id": 3,
          "text": "Anti-HBc"
        },
        {
          "id": 4,
          "text": "Anti-HBe"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Presence of <strong>a</strong><strong>nti-HBs</strong> with the absence of all other serological virus markers indicates <strong>immunity</strong> following <strong>HBV vaccination.&nbsp;</strong></p><hr><h3>Related Pearl: Interpretation of common serologic patterns in hepatitis B infection</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5552cae694994040b6b13be6442fc5adx1280x1466.JPEG\" alt=\"Pearl Image\"><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;<strong>Clinical Phases</strong></td>\n<td><span><strong>HBsAg</strong></span></td>\n<td><span><strong>Anti-HBs</strong></span></td>\n<td><span><strong>HBeAg</strong></span></td>\n<td><span><strong>Anti-HBe</strong></span></td>\n<td><span><strong>Anti-HBc</strong></span></td>\n<td><span><strong>HBV DNA</strong></span></td>\n</tr>\n<tr>\n<td><span>Acute HBV - Early-phase, high infectivity</span></td>\n<td>\n<p><span>+</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV -</span><span>Window phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgM</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Acute HBV - recovery phase</span></p>\n</td>\n<td>\n<p><span>-</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+/-</span></td>\n</tr>\n<tr>\n<td><span>Chronic HBV, high infectivity</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>+++</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Chronic HBV, low infectivity</span></p>\n</td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>IgG</span></td>\n<td><span>+</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the recent past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>HBV infection in the remote past</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>+/-</span></td>\n<td><span>IgG</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Post-vaccination</span></p>\n</td>\n<td><span>-</span></td>\n<td><span>+</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7607",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is false regarding HBV vaccination?",
      "choices": [
        {
          "id": 1,
          "text": "The current vaccine is prepared by cloning 'S gene' of HBV in Baker‚Äôs yeast"
        },
        {
          "id": 2,
          "text": "A single dose of HBV vaccine is recommended for high-risk groups for pre-exposure prophylaxis"
        },
        {
          "id": 3,
          "text": "For high-risk mothers who are seronegative, hepatitis B vaccine can be given during pregnancy."
        },
        {
          "id": 4,
          "text": "Hepatitis B vaccine should be administered intramuscularly in the deltoid muscle."
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Pre-exposure prophylaxis</strong> consists of administration of a <strong>3&ndash;4 dose </strong>series&nbsp;of <strong>h</strong><strong>epatitis B vaccine</strong> given over a <strong>6-month</strong> period.</p>\n<p>The pre-exposure prophylaxis of Hepatitis B vaccine <strong>schedule</strong> is as follows:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Group</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Vaccine dose in mL (Active ingredient in &micro;g/mL)</strong></p>\n</td>\n<td>\n<p><strong>&nbsp;Schedule</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Newborn</p>\n</td>\n<td>\n<p>&nbsp;0.5 mL (10&micro;g)</p>\n</td>\n<td>\n<p>&nbsp;&lt;24 hours, 6 weeks, 14 weeks (if administration of the first dose within 24 hours of birth is not possible, then 6, 10, and 14 weeks)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Healthy persons aged &le;19 years</p>\n</td>\n<td>\n<p>&nbsp;0.5 mL (10 &micro;g)</p>\n</td>\n<td>\n<p>&nbsp;0, 1, 2 / 6 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Healthy persons aged &ge;20 years</p>\n</td>\n<td>\n<p>&nbsp;1.0 mL (20 &micro;g)</p>\n</td>\n<td>\n<p>&nbsp;0, 1, 2 / 6 months</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Persons on hemodialysis or immunocompromised persons</p>\n</td>\n<td>\n<p>&nbsp;2.0 mL (40 &micro;g)</p>\n</td>\n<td>\n<p>&nbsp;0, 1, 2, 6 months</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<p>The vaccine is genetically engineered by cloning '<strong>S gene'</strong>&nbsp;in <strong>baker&rsquo;s yeast</strong>. It has non-glycosylated HBsAg particles given along with an alum adjuvant.</p>\n<p><strong>Pregnancy</strong> is <strong>not</strong> a <strong>contraindication</strong> for hepatitis B vaccination. The efficacy has been shown to be similar to that for non-pregnant adults, with overall seroconversion rates approaching 95 percent after three doses which can be taken during routine prenatal care.&nbsp;</p>\n<p>The vaccine is given <strong>intramuscularly,</strong> in the <strong>deltoid</strong> muscle and can be co-administered with other vaccines.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7609",
      "difficulty": "medium"
    },
    {
      "text": "A known case of hepatitis B going into hepatic failure is found to have a high viral load. Which of the following serological markers will not contribute to the viral load?",
      "choices": [
        {
          "id": 1,
          "text": "HBeAg"
        },
        {
          "id": 2,
          "text": "HBV DNA"
        },
        {
          "id": 3,
          "text": "HBV DNA polymerase"
        },
        {
          "id": 4,
          "text": "Anti-HBs"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Anti-HBs will not contribute to the high viral load, as it is not a marker of active viral replication.</p>\n<p><strong>HBeAg, HBV DNA, </strong>and HBV <strong>DNA polymerase</strong>&nbsp;are markers of <strong>active viral replication</strong> and will contribute to the high viral load.</p>\n<p><strong>HBeAg</strong> is a <strong>qualitative</strong> marker while&nbsp;<strong>HBV DNA</strong> is a <strong>quantitative</strong> marker of the replicative phase.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7610",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old man with heroin addiction presents with fatigue, palpable purpura, joint pains, and abdominal pain. Urine analysis shows massive proteinuria. Which of the following viruses should be tested for in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis A"
        },
        {
          "id": 2,
          "text": "Hepatitis C"
        },
        {
          "id": 3,
          "text": "Hepatitis D"
        },
        {
          "id": 4,
          "text": "Hepatitis E"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given clinical scenario is suggestive of <strong>mixed cryoglobulinemia</strong>, which is strongly associated with <strong>hepatitis C</strong>. Hence, the patient should be tested for hepatitis C.&nbsp;</p><hr><h3>Related Pearl: Extrahepatic Manifestations of Hepatitis B and C</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Hepatitis B</strong></td>\n<td><strong>Hepatitis C</strong></td>\n</tr>\n<tr>\n<td>Hematological</td>\n<td>\n<p>Aplastic anemia</p>\n</td>\n<td>\n<p>Essential mixed cryoglobulinemia</p>\n</td>\n</tr>\n<tr>\n<td>Renal</td>\n<td>\n<p>Membranous glomerulonephritis (hepatitis B &gt; C)</p>\n<p>Membranoproliferative glomerulonephritis</p>\n</td>\n<td>\n<p>Membranoproliferative glomerulonephritis</p>\n<p>Membranous glomerulonephritis &nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>Vascular</td>\n<td>\n<p>Polyarteritis nodosa (hepatitis B&gt;C)</p>\n</td>\n<td>\n<p>Leukocytoclastic vasculitis</p>\n</td>\n</tr>\n<tr>\n<td>Dermatologic</td>\n<td>\n<p>Erythema multiforme (Hepatitis B&gt;C)</p>\n<p>Urticaria</p>\n<p>Serum sickness</p>\n<p>Infantile papular acrodermatitis (Gianotti&ndash;Crosti syndrome)</p>\n<p>Erythema nodosum</p>\n</td>\n<td>\n<p>Erythema multiforme</p>\n<p>Sporadic porphyria cutanea tarda</p>\n<p>Lichen planus</p>\n<p>Necrolytic acral erythema</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Hepatitis C also increases the risk of:</p>\n<ul>\n<li>Non-Hodgkin&rsquo;s lymphoma</li>\n<li>Idiopathic thrombocytopenic purpura</li>\n<li>Autoimmune hemolytic anemia</li>\n<li>Diabetes mellitus</li>\n<li>Autoimmune thyroiditis &nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0939",
      "difficulty": "easy"
    },
    {
      "text": "Which hepatitis virus shows maximum chronicity in adults?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis A"
        },
        {
          "id": 2,
          "text": "Hepatitis E"
        },
        {
          "id": 3,
          "text": "Hepatitis C"
        },
        {
          "id": 4,
          "text": "Hepatitis D"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Maximum chronicity</strong>&nbsp;is seen in <strong>HCV infection</strong>, followed by HBV infection.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4a98233a27e046e7bd1407248af4406ax1200x992.JPEG\" alt=\"Explanation Image\"><p><strong>5-10%</strong> of adults infected with <strong>HBV </strong>develop chronic infection. The majority of neonates affected with hepatitis B develop chronic hepatitis.</p>\n<p><strong>HEV</strong> is associated with chronic infection only in <strong>immunocompromised</strong> individuals. HAV is not associated with chronicity.&nbsp;</p>\n<p>Note:&nbsp;The most common cause of <strong>post</strong>-<strong>transfusion&nbsp;hepatitis</strong> in developed countries is <strong>h</strong><strong>epatitis C</strong></p><hr><h3>Related Pearl: The Hepatitis Viruses</h3><table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>HAV</td>\n<td>HBV</td>\n<td>HCV</td>\n<td>HDV</td>\n<td>HEV</td>\n</tr>\n<tr>\n<td>Specific name</td>\n<td>Hepatovirus A</td>\n<td>Hepatitis B virus</td>\n<td>Hepacivirus C</td>\n<td>Hepatitis D virus</td>\n<td>Orthohepevirus A</td>\n</tr>\n<tr>\n<td>Family</td>\n<td>Picornaviridae</td>\n<td>Hepadnaviridae</td>\n<td>Flaviviridae</td>\n<td>Kolmioviridae (genus deltavirus)</td>\n<td>Hepeviridae</td>\n</tr>\n<tr>\n<td>Envelope</td>\n<td>Non enveloped</td>\n<td>Enveloped</td>\n<td>Enveloped</td>\n<td>Envelope from HBV</td>\n<td>Quasi-enveloped</td>\n</tr>\n<tr>\n<td>Nuclear material</td>\n<td>ssRNA</td>\n<td>Partially dsDNA</td>\n<td>ssRNA</td>\n<td>Circular defective ssRNA</td>\n<td>ssRNA</td>\n</tr>\n<tr>\n<td>Antigens</td>\n<td>HAV Ag</td>\n<td>HBsAg, HBcAg, HBeAg, HBxAg</td>\n<td>HCV Ag</td>\n<td>HBsAg, HDAg</td>\n<td>HEV Ag</td>\n</tr>\n<tr>\n<td>Antibodies</td>\n<td>Anti-HAV Ab</td>\n<td>Anti-HBs Ab, Anti-HBc Ab, Anti-HBe Ab</td>\n<td>Anti-HCV Ab</td>\n<td>Anti-HBs Ab, Anti-HDV Ab</td>\n<td>Anti-HEV Ab</td>\n</tr>\n<tr>\n<td>Auto-antibodies</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>Anti-LKM 1</td>\n<td>Anti-LKM 3</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>Routes of transmission</td>\n<td>Feco-oral, parenteral, sexual</td>\n<td>Perinatal, parenteral, sexual, percutaneous, direct mucosal contact</td>\n<td>Parenteral, perinatal, percutaneous, sexual</td>\n<td>Parenteral, sexual</td>\n<td>Feco-oral, zoonotic, vertical</td>\n</tr>\n<tr>\n<td>Incubation period</td>\n<td>30 days</td>\n<td>60 days</td>\n<td>50 days</td>\n<td>60 days</td>\n<td>40 days</td>\n</tr>\n<tr>\n<td>Chances of fulminant hepatic failure</td>\n<td>0.1%</td>\n<td>0.1 to 1%</td>\n<td>0.1%</td>\n<td>5% in coinfections and 20% in superinfections</td>\n<td>1-2% in adults and up to 25% in pregnant women</td>\n</tr>\n<tr>\n<td>Extrahepatic manifestations</td>\n<td>Rash, arthralgia</td>\n<td>Polyarteritis nodosa and membranous nephropathy</td>\n<td>Essential mixed cryoglobulinemia, MPGN, Metabolic syndrome</td>\n<td>&nbsp; &nbsp; &nbsp; -</td>\n<td>GBS, Bell&rsquo;s palsy, pancreatitis, &nbsp;and glomerulonephritis</td>\n</tr>\n<tr>\n<td>Resolution of acute infection</td>\n<td>2 months</td>\n<td>6 months</td>\n<td>6 months</td>\n<td>6 months</td>\n<td>3 months</td>\n</tr>\n<tr>\n<td>Progression to chronic infection</td>\n<td>No</td>\n<td>5-10%</td>\n<td>&gt;80%</td>\n<td>\n<p>10% of co-infections,</p>\n<p>90&ndash;100% of superinfections</p>\n</td>\n<td>\n<p>Only in immuno-compromised</p>\n</td>\n</tr>\n<tr>\n<td>HCC</td>\n<td>No</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n<td>May develop in chronic infections</td>\n</tr>\n<tr>\n<td>Vaccine</td>\n<td>Available</td>\n<td>Available</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-</td>\n<td>HBV vaccine</td>\n<td>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -</td>\n</tr>\n<tr>\n<td>Therapy</td>\n<td>None</td>\n<td>Entecavir, tenofovir, pegIFN-ùõÇ</td>\n<td>Velpatasvir, sofosbuvir, ribavirin</td>\n<td>PegIFN-ùõÇ</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7621",
      "difficulty": "easy"
    },
    {
      "text": "A patient with fulminant hepatitis is found to have coinfection with hepatitis B and hepatitis D viruses. Which of the following structures of HBV aid in the survival of HDV?",
      "choices": [
        {
          "id": 1,
          "text": "Reverse transcriptase"
        },
        {
          "id": 2,
          "text": "Envelope protein"
        },
        {
          "id": 3,
          "text": "Transcriptase to transcribe mRNA"
        },
        {
          "id": 4,
          "text": "Replicase enzyme"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Hepatitis D virus</strong>&nbsp;(HDV) is an incomplete/<strong>defective virus. </strong>It requires HBV, to provide the <strong>envelope protein&nbsp;</strong>(HbsAg) to aid in its survival.&nbsp;Hepatitis D is called&nbsp;the <strong>delta</strong>&nbsp;<strong>virus</strong>.</p>\n<p>Two types of infection may occur: &nbsp;</p>\n<ul>\n<li><strong>Co-infection -</strong> acute HDV and HBV infections occur simultaneously</li>\n<li><strong>Super-infection -</strong> Delta viral infection occurs in a person already harboring HBV. This most often leads to chronic hepatitis</li>\n</ul>\n<p>Coinfection and superinfection can cause fulminant hepatitis. <strong>HBV vaccination</strong> is <strong>protective</strong> against HDV.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7626",
      "difficulty": "medium"
    },
    {
      "text": "In the year 1955, following sewage contamination of drinking water in New Delhi, an outbreak of jaundice ensued. Electron microscopy of fecal samples from the affected population revealed a virus resembling caliciviruses. Which of the following was the etiological agent?",
      "choices": [
        {
          "id": 1,
          "text": "Hepatitis C"
        },
        {
          "id": 2,
          "text": "Hepatitis A"
        },
        {
          "id": 3,
          "text": "Hepatitis B"
        },
        {
          "id": 4,
          "text": "Hepatitis E"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Hepatitis E virus</strong>&nbsp;(HEV) resembles <strong>caliciviruses&nbsp;</strong>in morphology and physical characteristics. Hepatitis E is a <strong>non-enveloped</strong> virus with <strong>ssRNA</strong> genome</p>\n<p>Note: The largest HEV epidemic occurred in New Delhi in 1955-1956.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7627",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false about viral hepatitis?",
      "choices": [
        {
          "id": 1,
          "text": "Anti LKM-3 antibody is associated with hepatitis B infection"
        },
        {
          "id": 2,
          "text": "Anti-LKM1 antibodies are associated with hepatitis C infection"
        },
        {
          "id": 3,
          "text": "IgM anti-HAV antibody appears during the late incubation period"
        },
        {
          "id": 4,
          "text": "Enterically transmitted non-A, non-B hepatitis is caused by hepatitis E virus"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The<strong> anti-LKM-3 antibody</strong> is associated with <strong>hepatitis D</strong> infection, not hepatitis B.</p>\n<p>Anti&ndash;liver-kidney microsomal antibodies (anti-LKM) are many of several <strong>autoantibodies</strong> that are detected in the serum of patients with different types of acute or chronic <strong>liver disease.</strong> These antibodies are targeted against antigens of the <strong>cytochrome P450</strong> system.</p>\n<p>They are also associated with <strong>chronic hepatitis C</strong> and <strong>autoimmune hepatitis.</strong></p>\n<p>Option C: <strong>IgM</strong> anti-HAV antibody indicates <strong>current/recent</strong> infection. It appears during the late incubation period, peaks in 2-3 weeks, and disappears after 3-4 months.&nbsp;IgG denotes remote infection or immunity. It appears around the same time, peaks at 3-4 months, and persists for a long time.&nbsp;</p>\n<p>Option D: Hepatitis E infection was previously known as an epidemic or enterically transmitted non-A, non-B hepatitis. It is transmitted by feco-oral route.&nbsp;</p><hr><h3>Related Pearl: Antibodies in Hepatitis</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Antibodies </strong></td>\n<td><strong>Seen in </strong></td>\n</tr>\n<tr>\n<td>\n<p>ANA, ASMA, pANCA, anti-SLA/LP, AMA</p>\n</td>\n<td>\n<p>Autoimmune hepatitis Type 1</p>\n</td>\n</tr>\n<tr>\n<td>Anti-liver cytosol 1</td>\n<td>\n<p>Autoimmune hepatitis Type 2</p>\n</td>\n</tr>\n<tr>\n<td>Anti-LKM 1</td>\n<td>\n<p>Autoimmune hepatitis Type 2&nbsp;</p>\n<p>Chronic hepatitis C</p>\n</td>\n</tr>\n<tr>\n<td>Anti-LKM 2</td>\n<td>Drug-induced hepatitis</td>\n</tr>\n<tr>\n<td>Anti-LKM 3</td>\n<td>\n<p>Chronic hepatitis D</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<ul>\n<li>ANA: Anti-nuclear antibodies (most common antibody in autoimmune hepatitis)</li>\n<li>LKM: Liver&ndash;kidney microsomes</li>\n<li>SLA/LP: Soluble liver antigen/liver-pancreas</li>\n<li>ASMA: Anti-smooth muscle actin</li>\n<li>pANCA: Perinuclear anti-neutrophil cytoplasmic antibodies</li>\n<li>AMA: Antimitochondrial antibodies</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA7631",
      "difficulty": "medium"
    }
  ]
}